Rhythm Pharmaceuticals (RYTM) Non-Current Deferred Tax Liability (2021)

Rhythm Pharmaceuticals (RYTM) reported Non-Current Deferred Tax Liability of $8.0 million for Q3 2021, down 52.96% quarter-over-quarter from $17.0 million in Q2 2021.

Rhythm Pharmaceuticals (RYTM) Non-Current Deferred Tax Liability (2021) Analysis & Trends

Rhythm Pharmaceuticals (RYTM) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $8.0 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Rhythm Pharmaceuticals 6.59 Bn 6.25 Bn 52.96 Mn

Historic Data

Download Data
DateValue
Sep 30, 2021 7.99 Mn
Sep 30, 2021 7.99 Mn
Jun 30, 2021 16.98 Mn
Jun 30, 2021 16.98 Mn
Mar 31, 2021 22.01 Mn
Mar 31, 2021 22.01 Mn